Australian semiconductor company Archer Materials (ASX: AXE) has developed a novel graphene transistor test that will produce the most stable and accurate gFETs for future development activities and commercialisation of their biochip for the medical diagnostics industry. 

The new procedure, designed to scrutinise the gFET sensors under various conditions and electrical operation modes, was developed separate to their collaboration with several European foundries (chip manufacturers) while experimentation will now expand to the United States, a key market for medtech like Archer’s biochip. 

This initiative aims to fine-tune the functionality and reliability of the gFETs, which are integral components of Archer’s lab-on-a-chip that has the potential to diagnose for hundreds of different diseases from a single sample. 

The gFET sensors are critical for the biochip’s ability to detect substances quickly and accurately. The newly developed test procedure allows Archer to explore new ways to electrically operate the gFETs by adjusting the speed and direction of the voltage applied to the gate. These adjustments influence how the transistor responds to different liquids and the concentration of ions within them, ultimately determining the sensor’s sensitivity and speed.

By applying data analysis and machine learning, Archer’s new testing method can now detect substances under varying operating conditions more effectively, enhancing the biochip’s performance in diverse real-world applications.

Archer’s team has conducted extensive testing on the gFETs, focusing on factors such as electrical biasing conditions, the impact of repeated use, and exposure to different liquids. To further improve these aspects, Archer is developing proprietary materials modification steps and applying special ultrathin protective coatings to the transistors.

“The newly developed standard procedure for the extensive testing of gFETs will help improve the manufacture of the Biochip through our European foundry partners,” said Archer  Executive Chairman, Greg English. 

“This includes focusing on factors such as voltage settings and the impact of repeated use and liquid exposure. The Archer team discovered that the speed and direction of voltage applied to the gate significantly influence the transistor’s response. 

“By comparing gFET devices from different suppliers, Archer is identifying the most stable and accurate gFETs for future development activities and final use.” 

Archer’s collaboration with several foundries in Europe has been instrumental in developing and testing the gFETs. Recent work includes multi-project wafer runs with foundries in Germany, the Netherlands, and Spain, resulting in significant advancements in the biochip’s design and miniaturisation.

The ability to compare gFET devices from different suppliers is enabling Archer to identify the most stable and accurate gFETs for commercialisation where Archer can apply its findings to the most suitable foundry for their chips. 

The rigorous process is part of Archer’s fabless manufacturing strategy where the Company can leverage the specialties of foundries around the world rather than building their own which would require substantial capital expenditure. 

Undertaking this operating model where Archer is able to focus its resources towards R&D rather than operating expenses, reflected in their strong cash position of $20 million on 31 March 2024. 

Unveiling this new gFET test comes just one week after Archer appointed Dr Simon Ruffell as their Chief Technology Officer, having commenced with Archer in February 2024 and instrumental in their other major project – the 12CQ quantum project.